mRNA-1325
Phase 1Completed 0 views this week 0 watching
0
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Zika Virus
Conditions
Zika Virus
Trial Timeline
Dec 21, 2016 → Jul 31, 2019
NCT ID
NCT03014089About mRNA-1325
mRNA-1325 is a phase 1 stage product being developed by Moderna for Zika Virus. The current trial status is completed. This product is registered under clinical trial identifier NCT03014089. Target conditions include Zika Virus.
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03014089 | Phase 1 | Completed |
Competing Products
5 competing products in Zika Virus
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-1893 | Moderna | Phase 1 | 0 |
| mRNA-1893 | Moderna | Phase 2 | 0 |
| VLA1601 + Placebo | Valneva SE | Phase 1 | 23 |
| VLA1601 + CpG 1018® + 3M-052-AF | Valneva SE | Phase 1 | 23 |
| Zika Virus Immune Globulin (ZIKV-IG) | Emergent BioSolutions | Phase 1 | 19 |